


As an initial matter, Applicants wish to thank Examiner Zeman and SPE Examiner Smith for granting the Interview with Applicants' representative and for suggesting language that would overcome the prior rejections. As indicated in the Interview Summary, and as was discussed during the Interview, Applicants have now amended Claims 54 in the manner referred to, namely by deleting the term "consisting essentially of" while maintaining the Markush group. As discussed during the Interview, this amendment overcomes the rejection under 35 U.S.C. §112 and in addition overcomes the outstanding prior art rejections since none of the cited references, either singly or in combination, disclose or suggest the subject matter of amended Claim 54.

The only remaining issue is Applicants' entitlement to the priority document which would make moot the rejection on the basis of the Sun et al. article. Applicants enclosed herein as **APPENDIX 1** a summary of the pages of the priority document which give support to the claimed sequences.

In view of the foregoing, Applicants respectfully submit that the present application is in condition for immediate allowance, and such action is earnestly solicited.

Respectfully submitted,
LARSON & TAYLOR, PLC

February 27, 2003



B. Aaron Schulman
Registration No. 31877

1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
(703) 739-4900

ATTACHMENT A**Marked-Up Amended Claim**

Following herewith is a marked-up copy of the amended claim.

54. (Amended) A method of generating an antibody that binds to a fibronectin binding domain of a fibronectin binding protein and inhibits binding of said fibronectin binding protein to fibronectin, comprising administering to a human or animal a pharmaceutical composition comprising an immunologically effective amount of a peptide of a fibronectin binding domain of a fibronectin binding protein that does not bind to fibronectin, wherein said peptide ~~consists essentially of an amino acid sequence~~is selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12-55, 57, 59-86, 88-105.

ATTACHMENT B**Clean Amended Claim**

Following herewith is a clean copy of the amended claim.

54. (Twice amended) A method of generating an antibody that binds to a fibronectin binding domain of a fibronectin binding protein and inhibits binding of said fibronectin binding protein to fibronectin, comprising administering to a human or animal a pharmaceutical composition comprising an immunologically effective amount of a peptide of a fibronectin binding domain of a fibronectin binding protein that does not bind to fibronectin, wherein said peptide is selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12-55, 57, 59-86, 88-105.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent

In re patent application of: HOOK, et al

Serial No.: 09/010,317

Examiner: Zeman, Robert A.

Filed: January 21, 1998

Art Unit: 1645

For: FIBRONECTIN BINDING PROTEIN
COMPOSITIONS AND METHODS OF USE

Docket #: P06338US1/BAS

APPENDIX 1

As referred to in the amendment, and as requested by the Examiner, the following chart correlates the claimed SEQ ID NOS of the instant application with their support in the original provisional application, 60/036,139, filed January 21, 1997, and Applicant respectfully submits that the present application is entitled to the priority date of the priority document.

| Present Application 09/010,317 SEQ ID NO | Priority Document/ Provisional Application SEQ ID NO (if provided) | Page Number or Figure In The Priority Document/ Provisional Application 60/036,139 |
|--|---|---|
| 2 | --- | Fig. 10 |
| 4 | 56 | 88 |
| 6 | 39 | 88 |
| 8 | 47 | 88 |
| 10 | 15 | 82 |
| 12 | 51 | 85 |
| 13 | ²⁷ _{ak} 15 (from D3-P) | 88 |
| 14 | 9 | 82 |
| 15 | 10 | 82 |
| 16 | 11 | 82 |
| 17 | 12 | 82 |

| | | |
|----|----|----|
| 18 | 13 | 82 |
| 19 | 14 | 82 |
| 20 | 16 | 82 |
| 21 | 17 | 82 |
| 22 | 18 | 82 |
| 23 | 19 | 82 |
| 24 | 20 | 82 |
| 25 | 21 | 82 |
| 26 | 22 | 82 |
| 27 | 23 | 82 |
| 28 | 24 | 82 |
| 29 | 25 | 82 |
| 30 | 26 | 82 |
| 31 | 27 | 82 |
| 32 | 28 | 82 |
| 33 | 29 | 82 |
| 34 | 59 | 82 |
| 35 | 31 | 83 |
| 36 | 32 | 83 |
| 37 | 33 | 83 |
| 38 | 34 | 83 |
| 39 | 35 | 83 |
| 40 | 36 | 83 |
| 41 | 37 | 83 |
| 42 | 38 | 83 |
| 43 | 40 | 83 |
| 44 | 41 | 83 |
| 45 | 43 | 84 |
| 46 | 44 | 84 |
| 47 | 45 | 84 |

| | | |
|----|------|---------|
| 48 | 46 | 84 |
| 49 | 48 | 84 |
| 50 | 49 | 84 |
| 51 | 52 | 85 |
| 52 | 53 | 85 |
| 53 | 54 | 85 |
| 54 | 55 | 85 |
| 55 | 58 | 85 |
| 57 | 42 | 84 |
| 59 | 47 | Fig. 4A |
| 60 | ---- | 100 |
| 61 | ---- | 100 |
| 62 | ---- | 104 |
| 63 | ---- | Fig. 10 |
| 64 | ---- | Fig. 10 |
| 65 | ---- | Fig. 10 |
| 66 | ---- | Fig. 10 |
| 67 | ---- | Fig. 10 |
| 68 | ---- | Fig. 10 |
| 69 | ---- | Fig. 10 |
| 70 | ---- | Fig. 10 |
| 71 | ---- | Fig. 10 |
| 72 | ---- | Fig. 10 |
| 73 | ---- | Fig. 10 |
| 74 | ---- | Fig. 10 |
| 75 | ---- | Fig. 10 |
| 76 | ---- | Fig. 10 |
| 77 | ---- | Fig. 10 |
| 78 | ---- | Fig. 10 |
| 79 | ---- | Fig. 10 |

| | | |
|-----|-----|---------|
| 80 | --- | Fig. 10 |
| 81 | --- | Fig. 10 |
| 82 | --- | Fig. 10 |
| 83 | --- | Fig. 10 |
| 84 | --- | Fig. 10 |
| 85 | --- | Fig. 10 |
| 86 | --- | Fig. 11 |
| 88 | --- | Fig. 11 |
| 89 | --- | Fig. 11 |
| 90 | --- | Fig. 11 |
| 91 | --- | Fig. 11 |
| 92 | --- | Fig. 11 |
| 93 | --- | Fig. 11 |
| 94 | --- | Fig. 11 |
| 95 | --- | Fig. 11 |
| 96 | --- | Fig. 11 |
| 97 | --- | Fig. 11 |
| 98 | --- | Fig. 11 |
| 99 | --- | Fig. 11 |
| 100 | --- | Fig. 11 |
| 101 | --- | Fig. 11 |
| 102 | --- | Fig. 11 |
| 103 | --- | 105 |
| 104 | --- | 105 |
| 105 | --- | 104 |


CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the U.S.

Patent and Trademark Office (Fax No. 703/308-4242) on 27 February 2003.

B. Aaron Schulman
Registration No. 31,877

Signature: _____

A handwritten signature in black ink, appearing to read "B. Aaron Schulman", is written over a horizontal line.